Prime Medicine, INC

Prime Medicine announced a final arbitration award confirming its development candidate PM647 falls within its defined field, dismissing Beam Therapeutics' claims.

Prime Medicine, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of two Class I Directors and the ratification of its independent auditor.

Prime Medicine announced its first quarter 2026 financial results, highlighting progress in its gene editing therapies for Wilson Disease and AATD, with regulatory filings on track and initial clinical data expected in 2027.

Prime Medicine has appointed Svetlana Makhni as Chief Financial Officer, effective April 16, 2026, succeeding Dr. Allan Reine in the role.

Prime Medicine announced its full-year 2025 financial results and provided key business updates, including progress on its gene editing programs for Wilson Disease, AATD, and CGD.

Prime Medicine, Inc. announced an updated corporate presentation highlighting breakthrough clinical data for its Prime Editing platform and outlining key program advancements for Wilson Disease and AATD.

Prime Medicine reports a net loss of $49.1 million for Q1 2026, with increased G&A expenses due to arbitration, while R&D costs decrease as the company prioritizes its in vivo liver franchise.

Prime Medicine reported a reduced net loss for the quarter and significantly increased its cash position through a public offering, while advancing its gene editing pipeline and facing a legal dispute.

Prime Medicine, Inc. announced a new CEO, a strategic shift to liver disease programs, and a significant capital raise, alongside ongoing arbitration with Beam Therapeutics.

Prime Medicine's Q1 2025 results show a net loss and raise substantial doubt about its ability to continue as a going concern, despite ongoing research and development efforts.

Prime Medicine has entered into a significant research collaboration and license agreement with Bristol Myers Squibb, including a $55 million equity investment and potential for over $3.5 billion in milestone payments.

Prime Medicine, a biotechnology firm specializing in gene editing therapies, announced its second-quarter financial results for 2024, highlighting advancements in its research and development pipeline despite facing substantial financial challenges.

Prime Medicine reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing its gene editing pipeline and securing new collaborations.

Prime Medicine's 2024 10-K filing reveals a strategic focus on hematology, immunology, oncology, liver, and lung programs, alongside ongoing efforts in Prime Editing technology and key collaborations.

Prime Medicine's annual report details its progress in developing Prime Editing technology for various diseases, with plans to submit an IND for its lead candidate in the first half of 2024.

Prime Medicine, Inc. director David P. Schenkein acquired 75,000 stock options with an exercise price of $3.06, vesting under specific service conditions.

Prime Medicine, Inc. Director Jeffrey D. Marrazzo acquired 75,000 stock options with an exercise price of $3.06, vesting under specific service conditions.

Robert Nelsen, a Director and 10% owner of Prime Medicine, Inc., acquired 75,000 stock options on June 5, 2026.

Prime Medicine, Inc. reports that Director Michael Aaron Kelly was granted stock options for 75,000 shares.

Kaye I. Foster-Cheek, a Director at Prime Medicine, Inc., acquired 75,000 stock options.

Prime Medicine, Inc. reports that Director Wendy Chung acquired 75,000 stock options.

Prime Medicine, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 5, 2026, to elect directors and ratify auditor appointment.

Prime Medicine, Inc. is seeking stockholder approval for a one-time repricing of certain outstanding stock options for employees and directors, aiming to restore incentive value following a substantial decline in its common stock price.

Prime Medicine announces a strategic shift focusing on liver diseases and partnered programs, accompanied by a CEO transition and promising early clinical data for its Prime Editing technology.

Prime Medicine, Inc. is holding its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to vote on the election of directors and ratification of the company's independent auditor.

Prime Medicine will hold its 2025 annual meeting of stockholders virtually on June 4, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Prime Medicine's Board of Directors adopted Second Amended and Restated Bylaws to update corporate governance procedures, including those related to stockholder proposals, director nominations, and meeting protocols.

ARCH Venture Management and affiliated funds updated their Schedule 13D filing for Prime Medicine, Inc., reflecting a slight decrease in their percentage ownership due to a recent public offering despite a new share purchase.

T. Rowe Price Investment Management, Inc. has reduced its beneficial ownership in Prime Medicine Inc. to 3.3% of common stock.

T. Rowe Price Investment Management, Inc. has reported a 5.3% beneficial ownership stake in Prime Medicine Inc. common stock.

Alphabet Inc. and its affiliated investment entities have reported a combined beneficial ownership of 12.3% in Prime Medicine, Inc., totaling 16,562,498 shares.

FMR LLC and Abigail P. Johnson have reduced their beneficial ownership in Prime Medicine Inc. to 3.8% of common stock.

Newpath Partners, L.P. and its affiliated entities, including board member Thomas Cahill, have reported a beneficial ownership of 4.7% in Prime Medicine, Inc. common stock as of December 31, 2024, indicating a reduction from a previous filing.